These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 33987222)

  • 1. Day-90 survival in critically-ill patients with COVID-19 and hydroxychloroquine: a propensity analysis.
    Cour M; Amaz C; Bohé J; Rimmelé T; Ovize M; Argaud L
    Ann Transl Med; 2021 Apr; 9(7):524. PubMed ID: 33987222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality.
    Annie FH; Sirbu C; Frazier KR; Broce M; Lucas BD
    Pharmacotherapy; 2020 Nov; 40(11):1072-1081. PubMed ID: 33044019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.
    Guner R; Hasanoglu I; Kayaaslan B; Aypak A; Akinci E; Bodur H; Eser F; Kaya Kalem A; Kucuksahin O; Ates I; Bastug A; Tezer Tekce Y; Bilgic Z; Gursoy FM; Akca HN; Izdes S; Erdem D; Asfuroglu E; Hezer H; Kilic H; Cıvak M; Aydogan S; Buzgan T
    J Infect Public Health; 2021 Mar; 14(3):365-370. PubMed ID: 33647553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the impact of Hydroxychloroquine based regimens and standard treatment on COVID-19 patient outcomes: A retrospective cohort study.
    Almazrou SH; Almalki ZS; Alanazi AS; Alqahtani AM; Alghamd SM
    Saudi Pharm J; 2020 Dec; 28(12):1877-1882. PubMed ID: 33020690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU.
    Duška F; Waldauf P; Halačová M; Zvoníček V; Bala J; Balík M; Beneš J; Klementová O; Kozáková I; Kubricht V; Le Roy A; Vymazal T; Řehořová V; Černý V;
    Trials; 2020 Jul; 21(1):631. PubMed ID: 32641163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease.
    Satlin MJ; Goyal P; Magleby R; Maldarelli GA; Pham K; Kondo M; Schenck EJ; Rennert H; Westblade LF; Choi JJ; Safford MM; Gulick RM
    PLoS One; 2020; 15(7):e0236778. PubMed ID: 32701969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Hydroxychloroquine Use Is Not Significantly Associated with Positive PCR Results for SARS-CoV-2: A Nationwide Observational Study in South Korea.
    Bae S; Ghang B; Kim YJ; Lim JS; Yun SC; Kim YG; Lee SO; Kim SH
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33672785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19.
    Ruiz S; Concordet D; Lanot T; Georges B; Goudy P; Baklouti S; Mané C; Losha E; Vinour H; Rousset D; Lavit M; Minville V; Conil JM; Gandia P
    Int J Antimicrob Agents; 2021 Feb; 57(2):106247. PubMed ID: 33259916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Hydroxychloroquine on In-Hospital Mortality in COVID-19.
    Aboulenain S; Dewaswala N; Ramos F; Torres P; Abdallah A; Qader MA; Al-Abbasi B; Bornmann CR; Dziadkowiec K; Chen K; Pino JE; Chait R; de Almeida K
    HCA Healthc J Med; 2020; 1():425-431. PubMed ID: 37426837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study.
    Jung SY; Kim MS; Kim MC; Choi SH; Chung JW; Choi ST
    Clin Microbiol Infect; 2021 Apr; 27(4):611-617. PubMed ID: 33316402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19).
    Chen CP; Lin YC; Chen TC; Tseng TY; Wong HL; Kuo CY; Lin WP; Huang SR; Wang WY; Liao JH; Liao CS; Hung YP; Lin TH; Chang TY; Hsiao CF; Huang YW; Chung WS; Cheng CY; Cheng SH;
    PLoS One; 2020; 15(12):e0242763. PubMed ID: 33264337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir.
    Alosaimi B; Alshanbari HM; Alturaiqy M; AlRawi HZ; Alamri S; Albujaidy A; Bin Sabaan A; Alrashed AA; Alamer A; Alghofaili F; Al-Duraymih K; Alshalani AJ; Alturaiki W
    Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Effectiveness of Hydroxychloroquine and Azithromycin Combination Therapy for Treatment of Hospitalized Patients with COVID-19: A Propensity-Matched Study.
    Huang HD; Jneid H; Aziz M; Ravi V; Sharma PS; Larsen T; Chatterjee N; Saour B; Aziz Z; Nayak H; Trohman RG; Krishnan K
    Cardiol Ther; 2020 Dec; 9(2):523-534. PubMed ID: 33058086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Efficacy of Hydroxychloroquine in Patients with COVID-19: Findings from an Observational Comparative Study in Saudi Arabia.
    Alghamdi S; Barakat B; Berrou I; Alzahrani A; Haseeb A; Hammad MA; Anwar S; Sindi AAA; Almasmoum HA; Albanghali M
    Antibiotics (Basel); 2021 Mar; 10(4):. PubMed ID: 33807320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Data from the first wave of Covid-19 from the Central Military Hospital, Prague, Czech Republic.
    Bartovská Z; Andrle F; Beran O; Zlámal M; Řezáč D; Murinova I; Holub M
    Epidemiol Mikrobiol Imunol; 2020; 69(4):164-171. PubMed ID: 33445940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study.
    Gentry CA; Humphrey MB; Thind SK; Hendrickson SC; Kurdgelashvili G; Williams RJ
    Lancet Rheumatol; 2020 Nov; 2(11):e689-e697. PubMed ID: 32984847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.